Compare Ginkgo Bioworks Holdings Inc (DNA) vs FMC Corp (FMC) Price & Performance

Ginkgo Bioworks (DNA) trades at $11.34, down 1.13% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $312.76 million on $170.16 million revenue for 2025, with negative cash flow. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting ongoing strategic initiatives despite financial challenges.

The outlook remains speculative given persistent losses and cash burn, though analyst consensus is divided. Key risks include execution on revenue growth and path to profitability. Upside depends on successful commercialization of its biotech platform and partnerships, but high volatility and fundamental weakness warrant caution for investors.

FMC trades at $8.92, down 1.87% today, reflecting bearish technical signals and weak profitability. The stock shows negative net income margins and ROE, though recent quarterly EPS beat estimates. Cash flow trends are volatile, with 2025 showing negative operational cash flow but positive net cash flow from financing. Analyst consensus is mixed with a near-even split between Buy and Hold ratings, and a price target of $14.60 suggests potential upside. Recent news includes regulatory filings in Brazil and a minority equity investment.

Outlook: FMC faces significant headwinds from declining revenue and negative profitability, but aggressive deleveraging efforts and new product filings offer recovery potential. Risks include high debt, cyclical industry pressures, and execution challenges. The stock may appeal to value investors given low P/S and P/B ratios, but sustained earnings improvement is critical for long-term upside.